Investigators reviewed cases of patients with multiple sclerosis treated with alemtuzumab to determine the type and frequency of thyroid dysfunction.
First trimester exposure to anytithyroid drugs was associated with a greater risk of congenital malformations, especially for pregnant women who were given prescriptions for methimazole or both methimazole and propylthiouracil.
Patients given teprotumumab were more likely to experience a response at 24 weeks vs placebo.
In a randomized, double-blind study, Rituximab was more effective in treating Graves' orbitopathy than intravenous methylprednisolone.
Statins and thyroidectomy may delay or prevent thyroid-associated ophthalmopathy in Graves' disease.
Thyroid-specific autoantibody levels did not predict clinical features of Graves' disease, including ophthalmopathy or goiter.
Women should likely discontinue methimazole during pregnancy to prevent complications.
Rituximab did not perform better than a placebo in treating Graves' orbitopathy in a randomized controlled trial.
Endocrinology Advisor Articles
- ADA Releases Updated Guidelines for Managing Pediatric Type 1 Diabetes
- Relationship Between HbA1c and Coronary Artery Disease
- Intermittent vs Continuous Energy-Restricted Diet: Effects on Glycemic Control and Weight Loss T2D
- The Obesity Paradox in Diabetes: Conceptual and Clinical Approaches
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Self-Administered Contraceptive Vaginal System Approved for Up to 1 Year of Use
- Predictors of Weight Loss in Postpartum Women With Gestational Diabetes
- Genetic Screening May Predict Osteoporosis, Fracture Risk
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- AMA Adopts Policy on Augmented Intelligence